This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.
Program Description
Metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease linked to metabolic syndrome, is becoming an increasingly significant public health challenge. As a leading cause of liver-related morbidity, MASH contributes to the rising demand for liver transplantation and ongoing need for therapies that address both liver inflammation and the metabolic factors contributing to disease progression. Current standard of care involves lifestyle modifications, which often yield limited results. However, advances in treatment options have emerged, with an FDA-approved, orally administered partial activator of a thyroid hormone receptor therapy and several GLP-1 receptor agonists under investigation for MASH. This educational program will provide tools for specialty pharmacists to identify the clinical presentation of MASH, support timely interventions, and improve care delivery to alleviate the growing burden of MASH.
Target Audience: Managed care and specialty pharmacists
Type of Activity: Application
Release date: May 12, 2025
Expiration date: May 12, 2026
Learner level: Foundational
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Apply knowledge of updated metabolic dysfunction-associated steatohepatitis (MASH) terminology, epidemiology, and risk factors to identify patients at risk and guide management decisions
- Interpret current clinical guidelines for MASH to align patient care with recommended management strategies
- Investigate the efficacy and safety of current and emerging therapies for MASH to optimize treatment plans for individual patients
- Determine strategies for specialty and managed care pharmacists to enhance patient care through education, preventive care, and the integration of emerging therapies into clinical practice
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
